Broadwood Capital’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-5,292,156
| Closed | -$3.28M | – | 8 |
|
|
2018
Q4 | $3.28M | Hold |
5,292,156
| – | – | 0.46% | 8 |
|
|
2018
Q3 | $6.88M | Hold |
5,292,156
| – | – | 0.64% | 9 |
|
|
2018
Q2 | $7.14M | Hold |
5,292,156
| – | – | 0.82% | 9 |
|
|
2018
Q1 | $7.67M | Hold |
5,292,156
| – | – | 1.11% | 9 |
|
|
2017
Q4 | $11.9M | Buy |
5,292,156
+1,592,308
| +43% | +$4.03M | 1.66% | 9 |
|
|
2017
Q3 | $12.6M | Hold |
3,699,848
| – | – | 2.08% | 7 |
|
|
2017
Q2 | $13.1M | Hold |
3,699,848
| – | – | 2.42% | 7 |
|
|
2017
Q1 | $12.6M | Hold |
3,699,848
| – | – | 2.4% | 7 |
|
|
2016
Q4 | $17M | Hold |
3,699,848
| – | – | 2.89% | 7 |
|
|
2016
Q3 | $15.7M | Hold |
3,699,848
| – | – | 2.68% | 7 |
|
|
2016
Q2 | $8.88M | Buy |
3,699,848
+2,058,823
| +125% | +$7.44M | 1.72% | 8 |
|
|
2016
Q1 | $7.71M | Hold |
1,641,025
| – | – | 1.6% | 8 |
|
|
2015
Q4 | $6.45M | Hold |
1,641,025
| – | – | 1.09% | 9 |
|
|
2015
Q3 | $6.35M | Hold |
1,641,025
| – | – | 1.25% | 7 |
|
|
2015
Q2 | $7.55M | Buy |
1,641,025
+1,000,000
| +156% | +$9.59M | 1.29% | 6 |
|
|
2015
Q1 | $4.32M | Buy |
+641,025
| New | +$3.17M | 0.72% | 6 |
|
Broadwood Capital's AST Position: Q1 2019 in Review
Broadwood Capital sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 5,292,156 shares — an estimated $3.28M sold.
Broadwood Capital first reported a position in AST in Q1 2015 and held it in 16 quarters. The position peaked at $17M in Q4 2016. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- Broadwood Capital reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- Broadwood Capital sold 5,292,156 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $3.28M.
- Broadwood Capital first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2015 and held it in 16 quarters.
- Broadwood Capital's Asterias Biotherapeutics Inc. Series A position peaked at $17M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on Broadwood Capital's 13F filing for Q1 2019, filed 15 May 2019.